Millennium: The Takeda Oncology Company Release: Meta-Analysis of VELCADE® (bortezomib)-Based Induction Therapy Followed by Stem-Cell Transplantation Showed Significantly Greater Response and Longer Progression-Free and Overall Survival in Patients With M

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced data from a meta-analysis of VELCADE-based regimens compared to non-VELCADE-based regimens as induction therapy prior to autologous stem cell transplant (ASCT) in patients with previously untreated multiple myeloma (MM). These data were reported in an oral presentation at the 14th International Myeloma Workshop (IMW) held April 3-7, 2013 in Kyoto, Japan.